Barclays

Latest Barclays news and discussion

Sort by

Content type

Barclays· Finance · 9 sources · Sep 8, 2026Story

Rosen Law investigates securities claims against four entities

Rosen Law Firm is expanding securities investigations for investors in Coastal Financial, TruBridge, Barclays, and Flow (FLOW-USD), alleging that these companies issued misleading information and left shareholders with losses, with class actions being prepared where applicable. The firm emphasizes contingency fee arrangements and urges affected investors to join ongoing actions, citing notable stock declines tied to the disclosures.

Finance· Sep 8, 2026

+6

0CommentShare

Write a comment…

Barclays· Finance · 16 sources · Jul 24, 2026Story

HCA Healthcare Reports Strong Q2 Earnings, Revenue Rise

HCA Healthcare reported Q2 revenue of $20.23 billion, up 8.7% year over year, with net income of $1.699 billion and diluted EPS of $7.62, while adjusted EBITDA rose to $4.027 billion and the company kept its 2026 EPS guidance at $28.70–$30.50 as it cited higher uninsured volumes and lower surgical activity; the stock rose about 1.3%. Analysts pared their targets after softer Q2 results and guidance, with Wells Fargo trimming to $369 and Barclays to $402, while noting a need for stronger organic growth later in 2026.

Finance· Jul 24, 2026

+13

0CommentShare

Write a comment…

Barclays· Finance · 9 sources · Jul 22, 2026Story

Revolut Hits $115B Valuation in Secondary Sale

Revolut’s secondary share sale values the London fintech at about $115 billion, with shares priced at $2,017 and the valuation more than 50% higher than last year, cementing its status as Europe’s most valuable startup. The move follows a full UK banking license, rapid user growth to over 70 million, and continued investor confidence across multiple markets.

Finance· Jul 22, 2026

+6

0CommentShare

Write a comment…

Barclays· Finance · 7 sources · Jul 22, 2026Story

Analysts Trim Celldex Price Targets, Shares Fall

Celldex Therapeutics faces a flurry of analyst revisions, with Cantor Fitzgerald and Canaccord Genuity trimming targets to 61 and 60 while maintaining overweight/buy ratings, and Morgan Stanley lowering its target to 40, reflecting mixed sentiment. Meanwhile, firms like Guggenheim and Wells Fargo have raised targets to around 100 and 54 respectively, indicating a broad range of views on the stock’s near-term prospects as it trades in the mid-30s.

Finance· Jul 22, 2026

+4

0CommentShare

Write a comment…